Citations 14
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials
Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. , Minasian, Lori M. , Kelly, William Kevin, O’Mara, Ann M., Denicoff, Andrea , Seisler, Drew K., Atherton, Pamela J., Heist, Rebecca S. , Himelstein, Andrew L., Sikov, William M. , Weckstein, Douglas, Lake, Diana, Biggs, David D., Kuzma, Charles, Kirshner, Jeffrey J., Atherton, Philip J. , Seisler, Drew, Dueck, A. C. , Basch, Ethan , Atherton, Pamela J., Paskett, Electra D. , Carey, Lisa A. , Dickler, Maura N. , Rugo, Hope S. , Socinski, Mark A. , Venook, Alan P. , Freedman, Rachel A. , Schrag, Deborah , Atherton, Philip J.
JAMA Oncology | February 16, 2017 | Volume: 3 | Issue: 8 | Pages: 1043
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Dueck, Amylou C. , Mendoza, Tito R. , Castro, Kathleen M. , Rogak, Lauren J. , Atkinson, Thomas M. , Denicoff, Andrea , O’Mara, Ann M., Li, Yuelin , Clauser, Steven B., Bryant, Donna , Bearden, James D. , Gillis, Theresa A. , Harness, Jay K., Siegel, Robert D. , Cleeland, Charles S. , Sloan, Jeff A. , Bruner, Deborah Watkins , Minasian, Lori M. , Basch, Ethan , Dueck, A. C. , Mitchell, Sandra A , Reeve, Bryce B. , Bennett, Antonia V , Paul, Diane Β. , Schrag, Deborah , Abernethy, Amy P. , Basch, Ethan , Bruner, Deborah , Mendoza, Tito , Li, Yuelin
JAMA Oncology | August 13, 2015 | Volume: 1 | Issue: 8 | Pages: 1051
Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217)
Gritz, Ellen R., Arnold, Kathryn B. , Moinpour, Carol M. , Burton‐Chase, Allison M. , Probstfield, Jeffrey F., See, William A., Lieber, Michael M., Caggiano, Vincent , Moody‐Thomas, Sarah, Szczepanek, Connie M. , Ryan, Anne, Carlin, Susie M., Hill, Shannon , Goodman, Phyllis J. , Padberg, Rose Mary, Minasian, Lori M. , Meyskens, Frank L. , Thompson, Ian M. , Tangen, Catherine M. , Thompson, Ian M
Cancer Epidemiology, Biomarkers & Prevention | July 16, 2014 | Volume: 23 | Issue: 8 | Pages: 1638-1648
Abstract Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebo-controlled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6, 13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P < 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P < 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials. Cancer Epidemiol Biomarkers Prev; 23(8); 1638–48. ©2014 AACR.
Conducting Cancer Control and Survivorship Research via Cooperative Groups: A Report from the American Society of Preventive Oncology
Demark‐Wahnefried, Wendy , Mustian, Karen M. , Minasian, Lori M. , Rowland, Julia, Sprod, Lisa K., Janelsins, Michelle C. , Peppone, Luke J. , Sloan, Jeff A. , Engquist, Karen Basen, Palesh, Oxana Gronskaya , Jones, Lee W. , Buist, Diana S.M. , Paskett, Electra D. , Demark-Wahnefried, Wendy
Cancer Epidemiology, Biomarkers & Prevention | May 5, 2011 | Volume: 20 | Issue: 5 | Pages: 1050-1055
Abstract As the number of cancer survivors expands, the need for cancer control and survivorship research becomes increasingly important. The National Cancer Institute (NCI) Cooperative Groups may offer a viable platform to perform such research. Observational, preventive, and behavioral research can often be performed within the cooperative group setting, especially if resources needed for evaluation are fairly simple, if protocols are easily implemented within the typical clinical setting, and if interventions are well standardized. Some protocols are better suited to cooperative groups than are others, and there are advantages and disadvantages to conducting survivorship research within the cooperative group setting. Behavioral researchers currently involved in cooperative groups, as well as program staff within the NCI, can serve as sources of information for those wishing to pursue symptom management and survivorship studies within the clinical trial setting. The structure of the cooperative groups is currently changing, but going forward, survivorship is bound to be a topic of interest and one that perhaps may be more easily addressed using the proposed more centralized structure. Cancer Epidemiol Biomarkers Prev; 20(5); 1050–5. ©2011 AACR.